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Abstract
Background—The effectiveness of counseling messages to avoid unprotected sex during short-
term treatment for curable sexually transmitted infections is unknown.
Methods—We randomized 300 female STI clinic patients 18 years or older with cervicitis and/or
vaginal discharge in Kingston, Jamaica, in 2010 to 2011, to 1 of 2 counseling messages for their
course of syndromic treatment: abstinence only or abstinence backed up by condom use. At a
follow-up visit 6 days afterward, we collected vaginal swabs to test for prostate-specific antigen
(PSA), a biological marker of recent semen exposure, and administered a questionnaire assessing
sexual behavior.
Results—No differences were found in the proportions of women testing positive for PSA at
follow-up in the abstinence-plus-condom group (11.9%) and abstinence-only group (8.4%) (risk
difference, 3.5; 95% confidence interval, −3.5 to 10.5). There also was no significant difference in
reporting of unprotected sex between groups. Reporting a history of condom use before
enrollment significantly modified the effect of counseling arm on PSA positivity (P = 0.03).
Among those reporting recent condom use, 10.3% in the abstinence-only arm and 4.8% in the
abstinence-plus-condom arm tested positive for PSA. Conversely, among those not reporting
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recent condom use, 6.5% in the abstinence-only arm and 17.3% in the abstinence-plus-condom
arm had PSA detected.
Conclusions—We found no evidence to support the superiority of either counseling message.
Post hoc analyses suggest that women with recent condom experience may benefit significantly
more from abstinence-plus-condom messages, whereas women without such experience may
benefit significantly more from abstinence-only messages. Providers should weigh individual
condom use history when determining the most appropriate counseling message.
The World Health Organization estimates 340 million new cases of sexually transmitted
infections (STIs) occur annually worldwide, with the rate of new infections in Latin
America and the Caribbean second only to that of sub-Saharan Africa.1 Because STIs
increase risk for adverse health outcomes such as HIV,2,3 preventing patients with newly
diagnosed, curable STIs from infecting their partners is crucial. The main strategy for
preventing secondary infections involves counseling index patients either to abstain from
sex while they remain infectious or to use condoms consistently and correctly to protect
against the transmission of STIs spread primarily through skin-to-skin contact or, to a lesser
degree, those spread by contact with mucosal surfaces.4
The effectiveness of abstinence-only interventions, in general, has not been demonstrated.5
although abstinence-based interventions combined with safer-sex strategies such as condom
use may reduce self-reported behaviors, data on their effectiveness against biological
outcomes is limited.6 Furthermore, evidence from the few trials conducted, which involve
long-term behavior changes, might not be applicable in the context of preventing
transmission from patients with curable infections during their short-term course of
treatment. Guidelines from the Centers for Disease Control and Prevention and other bodies
recommend complete abstinence but do not recommend or mention the use of condoms in
this situation.4,7 Conversely, the Jamaican Ministry of Health recommends both abstinence
and condom use interventions in their written guidance, which has resulted in patients
receiving either of 2 counseling messages for the treatment period: abstinence or abstinence
backed up by condom use in case sex was to occur.8 Given their unknown relative
effectiveness, we conducted a pilot randomized controlled trial using a biological marker of
recent semen exposure detected in vaginal fluid as a proxy of recent unprotected vaginal




The Assessing Counseling Message Effectiveness Study randomized 300 women attending a
public STI clinic in Kingston, Jamaica, from August 2010 to March 2011, to receive 1 of 2
counseling messages: (1) a single message promoting short-term abstinence (“abstinence
only”) or (2) a hierarchical message promoting abstinence backed up by the promotion and
provision of condoms (“abstinence plus condom”). Eligible women were at least 18 years of
age, prescribed syndromic treatment for cervicitis and/or vaginal discharge according to
standard clinical care (and hence were eligible to receive a counseling message for
abstaining from coitus), and had no antibiotic use in the past 14 days. Pregnant or HIV-
positive women were ineligible because these populations could have differed in unknown
ways from other women with respect to likelihood of adherence to the counseling messages.
We prepared sequentially numbered and sealed, opaque envelopes containing the
randomized assignment using permuted block randomization with the order generated by a
pseudorandom number generator using a fixed, preselected parameter. Although masking
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participants and clinic study staff to arm assignment was not feasible, staff analyzing the
data and laboratory staff remained masked until the analyses were completed.
We assessed prospective participants who gave written consent for screening for pregnancy
and HIV status and performed a pelvic examination. Patients found to be syndromically
positive for cervicitis and/or vaginal discharge received the recommended treatment regimen
specified by the Jamaican Ministry of Health.8 Standard clinical practice was followed for
referring their partners for care. A study clinician collected vaginal swabs for immediate
testing for STIs and for later testing for prostate-specific antigen (PSA), which is a
biomarker of semen detectable for up to 48 hours postexposure.9 Women eligible after
screening could give written consent for study enrollment. The clinician read the assigned
counseling message aloud to participants using scripts standardized for the trial (Panel).
Staff verbally administered a quantitative questionnaire to collect information on
demographics, sexual activity, and condom use. We decided a priori not to use audio
computer-assisted self-interviewing to collect the quantitative data because this method has
not been definitively proven to improve the validity of self-reports of sexual behavior.10
A single follow-up visit was scheduled 6 days after enrollment to coincide with the time
most participants would still be on syndromic treatment and thus subject to adhere to their
assigned counseling message. At the follow-up visit, staff again collected vaginal swabs for
STI and later PSA testing and administered a questionnaire. At the end of the visit, we asked
the participants for written consent to retroactively test their already collected vaginal swabs
from both the enrollment and follow-up visits for the presence of PSA. We used this
sequence of procedures to minimize bias from participants modifying their sexual behavior
or their reporting of sexual behavior, (independent of the counseling message provided) as a
result of having prior knowledge of the biomarker testing. We subsequently destroyed swabs
from participants who did not provide consent for retroactive PSA testing. Ethical review
boards at the Jamaican Ministry of Health and the Centers for Disease Control and
Prevention approved the research.
Laboratory Testing
We tested vaginal swabs collected from the 2 study visits on-site with ABAcard p30
(Abacus Diagnostics, West Hills, CA; ~ 4.50 per test), a rapid, semiquantitative test for
PSA, following published procedures.11 In brief, vaginal swab eluate was added to the
sample well of the cassette and allowed to incubate for 10 minutes at room temperature.
Cassettes with a visible line in the control area but not the test area were interpreted as
negative for PSA, whereas those with visible test and control lines were graded as low or
high positive for PSA based on the intensity of the pink test line compared with PSA
standards. High positives corresponded to standard solutions containing 23 ng PSA/mL or
greater; low positives corresponded to standard solutions containing 4 to less than 23 ng
PSA/mL. We performed quality assurance by testing a second swab from the first 82
participants using a quantitative test (Abbott Diagnostics, Abbott Park, IL) at the University
of North Carolina at Chapel Hill. Using the quantitative test as the reference standard, we
found 100% sensitivity and 98.8% specificity for the ABAcard results when their outcomes
were classified as low or high positive versus negative and 100% sensitivity and 100%
specificity when their outcomes were classified as high positive versus low or negative.
We diagnosed STIs on-site using the APTIMA Combo2 Assay (Gen-Probe, Inc.; San Diego,
CA) for detection of Neisseria gonorrhoeae and Chlamydia trachomatis nucleic acids
according to the manufacturer's instructions. Trichomonas vaginalis nucleic acids were
detected using the APTIMA TV Analyte Specific Reagents (Gen-Probe, Inc.) as previously
described.12
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To compare the relative effectiveness of the 2 counseling messages, we calculated the risk
difference (RD), with a 95% confidence interval (CI) of testing positive for PSA at follow-
up. We used an intent-to-treat analysis of participants with non-missing PSA data from the
follow-up visit; sensitivity analyses included restricting the analysis to the per-protocol
population of participants who attended their follow-up visit on the scheduled date or 1 day
before or after. We also evaluated outcomes based on (1) reclassifying the PSA test result to
negative or low positive PSA versus high positive and (2) using self-reported lack of
unprotected vaginal sex instead of the biological outcome.
Based on limited evidence from studies measuring the proportions of women testing positive
for PSA,10,13–16 2 of which were conducted among non-sex worker populations,10,16 we
estimated that 20% of participants would test positive for PSA at the follow-up visit. Using a
2-tailed test with α value of 0.025 and 80% power, a sample size of 300 would permit the
rejection of the null hypothesis of no difference between arms if the incidence of PSA in one
arm were 20% and the incidence in the more effective arm were 8% (i.e., RD of 0.12). We
followed CONSORT guidelines for the reporting of the results.17
RESULTS
Study Population
Of 495 women attending the STI clinic who were invited to screen for the study, 116 were
not interested in learning about the study, 23 women declined to consent, and 56 did not
meet the eligibility criteria (Fig. 1). Thus, we enrolled and randomized 300 women in the
study in a balanced ratio (150 in each arm) to receive one of the counseling messages. Seven
women failed to return for follow-up, and an additional 7 declined consent for PSA testing.
Consequently, the intent-to-treat population consisted of 286 women (95.3% of those
randomized), equally balanced by study arm (143 in each arm).
Altogether 29% of the participants were single, 36% had a visiting partner (understood as a
conjugal partner who does not live with her),18 and 34% were married or cohabiting (Table
1). Participants had a median of 11 years of education, 2 prior births, and 1 sexual partner in
the past 3 months. Women in the abstinence-only arm were slightly younger than those in
the abstinence-plus-condom arm (median of 27 and 29 years, respectively). Women in the
abstinence-only arm were more likely to report having used a condom in the past 3 months
compared with women in the abstinence-plus-condom arm (56% vs. 43%, respectively).
Similarly, women in the abstinence-only arm were more likely to report currently using
condoms for contraception compared with those in the abstinence-plus-condom arm (31%
vs. 19%, respectively).
Effectiveness of Counseling Messages
Approximately 10% of participants overall had biologic evidence of recent unprotected
intercourse detected at the follow-up visit. The proportion of women with PSA detected was
slightly higher in the abstinence-plus-condom group (11.9%) compared with the abstinence-
only group (8.4%), although the difference was not statistically significant (RD, 3.5; 95%
CI, 3.5–10.5) (Table 2). Adjusting for potential confounders included in Table 1 had little
effect on the primary effect estimate (data not reported). Repeating the analyses using the
per-protocol population (i.e., restricting the analysis to those who returned 5–7 days after
enrollment) had only a minimal effect on estimates (data not shown). No significant
differences were found between groups in analyses of any other of the measured secondary
outcomes (Table 2), including those based on self-reported sexual behavior. For example,
there was no significant difference in reporting of unprotected sex since the enrollment visit
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between the abstinence-plus-condom group (17.9%) and the abstinence-only group (11.7%)
(RD, 6.2; 95% CI, −2.1 to 14.5). Overall, 19.6% (n = 56) of women (23.1%, abstinence plus
condom; 16.1% abstinence only) at the follow-up visit reported having unprotected vaginal
sex since enrollment or tested positive for PSA.
Reporting a history of condom use during sex in the 3 months before enrollment
significantly modified the effect of the counseling arm on whether PSA was detected at the
follow-up visit (P = 0.03). Among 140 women who reported using a condom during sex in
the past 3 months, 4.8% in the abstinence-plus-condom arm and 10.3% in the abstinence-
only arm tested positive for PSA at follow-up (RD, −5.4%; 95% CI, −14.0% to 3.2%). In
contrast, among 143 women who reported no condom use during the past 3 months, 17.3%
in the abstinence-plus-condom arm and 6.5% in the abstinence-only arm had PSA detected
at follow-up (RD, 10.8; 95% CI, 0.6%–21.1%).
DISCUSSION
Overall, we found no evidence in the randomized comparisons to support the superiority of
either of the 2 counseling messages for avoiding unprotected sex during the treatment period
for selected curable STIs or reproductive tract infections in this pilot randomized controlled
trial. The proportion of female STI clinic patients who were counseled on abstinence or
abstinence backed up by condom use did not significantly differ in their risk of having a
biomarker of semen exposure detected approximately 1 week after being prescribed
treatment or in self-reported sexual behavior. The present study differed from prior studies
of behavioral interventions among patients at STI clinics19,20 in 2 regards: the use of an
objective biomarker of semen exposure and the focus on sexual behavior during the short
period of STI treatment.
Our findings from a post hoc analysis suggest that counseling message effectiveness was
modified by participants' recent experience using condoms. Women with experience with
condoms may benefit significantly more from the hierarchical message that included
condoms, whereas women without such experience may benefit significantly more from the
abstinence-only message. A similar effect regarding male condom use at baseline was found
in a randomized crossover trial comparing the female condom with the male condom among
women attending a family planning clinic in Brazil.21 Although the 2 condom types in that
study had similar rates of moderate or high concentrations of PSA detected in postcoital
specimens, women who reported experience at baseline with using male condoms appeared
to have an increased risk of PSA when they used the female condom.
These findings suggest that providers should weigh the patient's condom use history when
determining the best counseling message and prevention approach for an individual patient.
Client-centered counseling has previously been shown to be associated with reduced rates of
STIs and increased rates of self-reported condom use.22 Future research could use semen
biomarkers to evaluate the effectiveness of client-centered counseling, especially among
patients with a syndromic or laboratory-confirmed STI diagnosis who currently already
receive routine counseling.
The lack of a significant difference observed between counseling messages could be
attributable to several factors. For example, the brief counseling messages administered
could have been insufficient to differentially influence sexual behavior among patients
recently diagnosed as having infection above and beyond existing preventive approaches.
The Jamaican Ministry of Health has a comprehensive HIV program, which already includes
educational campaigns on condom use and social marketing of condoms.23 Thus, any
differences between the 2 counseling messages could have been diluted to the extent that
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participants in the abstinence-only arm were exposed to condom messages or condom
products outside the study context.
Given that the 10% observed incidence of PSA positivity was markedly lower than
anticipated, the pilot trial likely was underpowered to detect statistically significant
differences between intervention arms. Although we were able to ascertain whether a large
difference existed in the effectiveness of the 2 messages, further research would be needed
to rule out a smaller difference. Furthermore, despite providing comparative evidence of
relative effectiveness, the trial results are non-informative as to the magnitude of
effectiveness of the counseling messages for avoiding unprotected vaginal sex during the
treatment period. The proportion of women with a positive PSA biomarker detected at
follow-up is an underestimation of the proportion who actually engaged in unprotected sex
during the observation period, as an estimated 71% of exposed women will test negative by
24 hours, and by 48 hours, almost none will have identifiable PSA.9 Thus, the observed PSA
rate of 10% should be interpreted as the lower bound of the frequency of exposure during
the treatment interval, which suggests that an intervention more intensive than the brief
counseling messages studied here may be needed to modify women's sexual behavior. We
noted, however, that similar study results were observed when unprotected sexual behavior
was used as study outcomes.
Depending on its feasibility in other contexts, studies could use repeated sampling with PSA
testing to facilitate objective measurement of sexual behavior over longer periods. Testing
for Y-chromosome as an additional biomarker of recent sexual activity was not feasible in
this study because its longer window of detection (i.e., up to 14 days) could have detected
semen exposures that preceded study enrollment.24 However, given that the clearance and
detection of PSA are unlikely to be strongly influenced by confounders, we believe that this
biomarker provides an appropriate unbiased comparison of relative exposure to semen.
A strength of the trial was the high retention rate: 95% of randomized women were
successfully observed and included in the intent-to-treat population. The high completion
rate likely was a result of the short (6-day) interval required for follow-up combined with the
use of active tracing of enrolled women. Women also might have been motivated to return
to learn their STI test results. Another strength was the trial design, in which women were
approached for consent for PSA testing of already collected vaginal swabs only after they
had completed the quantitative interview at the follow-up visits. This temporality of
procedures ensured that advance knowledge of biomarker testing did not alter participant
behavior before their visit or influence their reporting of behaviors, although limited
research suggests that advance knowledge that specimens will be tested for objective
biomarkers might not influence participants' reports of recent unprotected sex.25
Finally, the study strongly benefited from the use of an objective biomarker for evaluating
the effectiveness of the HIV/STI prevention counseling messages in addition to self-reported
data. Beyond participants' actual sexual behavior, participant reporting of this behavior to
investigators, for example, could have been influenced by the particular counseling message
received. The trial also represents among the first efforts to incorporate testing of a semen
biomarker in an HIV/STI intervention trial using a rapid, on-site assay, and its successful
implementation demonstrates the feasibility of developing local capacity to conduct the
inexpensive, on-site testing.11,26
In summary, we found no evidence supporting the superiority of promoting either abstinence
or abstinence backed up by condoms in leading women to avoid unprotected intercourse
during the treatment period for curable STIs and other reproductive tract infections.
Treatment guidelines for STDs in the United States and Europe, for example, call for
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abstinence-only counseling in this situation to reduce risky sexual behavior.4,7 The evidence
base underlying this recommendation for sexually active individuals is limited, however,
and the current findings suggest that a comprehensive prevention message that includes
condom use may also be appropriate.
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Disposition of potential participants.
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Panel
Scripts for study counseling messages.
Abstinence No sex. It is important that you do not have sex until after you have been checked by the doctor. You will see the
doctor again next week, when you return for your follow-up appointment. It is important that you take all of your
medication. It is important that you come back next week for your follow-up appointment.
Sex may cause the medication to seem not to work because of reinfection or infection with other sexually
transmitted germs.
Sex may cause your partner(s) to be infected and make it possible for you to be infected again.
Abstinence plus condom No sex. It is important that you do not have sex until after you have been checked by the doctor. You will see the
doctor again next week, when you return for your follow-up appointment. It is important that you take all of your
medication. It is important that you come back next week for your follow-up appointment.
If you are going to have sex, it is important that your partner uses a condom each time.
Sex without a condom may cause the medication to seem not to work because of reinfection or infection with other
sexually transmitted germs.
Sex without a condom may cause your partner(s) to be infected and make it possible for you to be infected again.
Male condoms will be supplied and proper condom use explained.
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TABLE 1
Characteristics and Behaviors at Enrollment by Counseling Arm for Intent-to-Treat Population (N = 286)
Characteristic Abstinence Only (n = 143) Abstinence + Condom (n = 143)
Age, median (IQR), y 27 (23–32) 29 (23–38)
Parity, median (IQR) 2 (1–3) 2 (1–3)
No. male partners in the past 3 mo, median (IQR), y 1 (1–2) 1 (1–2)
Relationship status
 Single 42 (29.4) 39 (27.3)
 Visiting partner* 52 (36.4) 54 (37.8)
 Married or cohabiting 49 (34.3) 50 (35.0)
Used a condom in the past 3 mo
 Yes 78 (55.7) 62 (43.4)
 No 62 (44.3) 81 (56.6)
Current contraceptive method
 Condoms 44 (31.2) 27 (18.9)
 Injectable contraceptive 26 (18.2) 28 (19.6)
 Oral contraceptive 13 (9.1) 15 (10.5)
 Other 19 (13.3) 20 (14.0)
 None 41 (28.7) 53 (37.1)
Self-reported vaginal sex in the past 2 d
 No vaginal sex 111 (77.6) 106 (74.1)
 Protected vaginal sex only 12 (8.4) 11 (7.7)
 ≥1 unprotected vaginal act >1 laboratory-diagnosed STI at enrollment 20 (14.0) 26 (18.2)
 Yes 54 (38.0) 56 (39.7)
 No 88 (62.0) 85 (60.3)
PSA detection
 Yes 10 (7.0) 14 (9.9)
 No 133 (93.0) 128 (90.1)
Values are presented as no. (%), unless otherwise indicated.
*
Understood as a conjugal partner who does not live with her.
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TABLE 2
Unprotected Sex Measured at Follow-up Visit by Counseling Arm for Intent-to-Treat Population (N = 286)




No. % No. %
Primary analysis
 Positive for PSA
  Yes 17 11.9 12 8.4 3.5% (−3.5%–10.5%) 1.42 (0.70–2.86)
  No 126 88.1 131 91.6
Secondary analyses
 High positive for PSA
  Yes 11 7.7 8 5.6 2.1% (−3.7%, 7.9%) 1.38 (0.57–3.32)
  No 132 92.3 135 94.4
 Reported unprotected sex since
enrollment visit
  Yes 25 17.9 16 11.7 6.2% (−2.1%, 14.5%) 1.53 (0.85–2.74)
  No 115 82.1 121 88.3
 Reported unprotected sex in 2 d
before follow-up visit
  Yes 8 5.6 7 4.9 0.7% (−4.4%, 5.9%) 1.15 (0.43–3.09)
  No 134 94.4 136 95.1
 No. of unprotected acts reported in
2 d before follow-up visit
Median, 0; range, 0–2 Median, 0; range, 0–3 – –
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